• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Boston Scientific (BSX) Faces Device Recalls, Is It Still A Bargain?

    Simply Wall St·08/09/2026 09:30:54
    语音播报

    Boston Scientific (BSX) is under close watch after a series of voluntary Class II device recalls affecting FARADRIVE steerable sheaths and FARASTAR pulsed field ablation generators used in cardiac and vascular procedures worldwide.

    See our latest analysis for Boston Scientific.

    The Boston Scientific share price has climbed in the last month, with a 30 day share price return of 10.14% and a 7 day gain of 5.52%. However, momentum has faded over the past quarter, with a 90 day share price return that declined 7.61% and a year to date share price return that declined 47.94%. Over a longer horizon, total shareholder return is mixed, with a 1 year total shareholder return that declined 52.19% but a 5 year total shareholder return of 11.23%, as investors weigh recent voluntary recalls against the latest earnings update and revised guidance.

    If safety issues in cardiac devices have your attention, it can be useful to see how other healthcare focused AI opportunities are priced and growing via the Simply Wall St screener for 43 healthcare AI stocks

    The sharp pullback this year, along with a recent bounce, leaves Boston Scientific at an awkward midpoint between concern over recalls and confidence in its earnings and guidance. How far does the current share price reflect either side of that story?

    Most Popular Narrative: 31.8% Undervalued

    Compared with the last close at $49.31, the most followed Boston Scientific narrative points to a fair value of $72.25, which is a sizeable gap that analysts tie to long term growth, margins and capital allocation plans.

    Investment in proprietary, high-margin technologies (e.g., next-gen mapping, advanced diagnostic tools, differentiated urology/neuromodulation pipelines) combined with successful integration of recent acquisitions (Axonics, SoniVie, Intera, Silk Road) expands Boston Scientific's addressable market and is likely to drive margin expansion as product mix improves.

    Read the complete narrative. Read the complete narrative.

    If you want to understand why this valuation is higher than where Boston Scientific trades today, focus on the interplay of projected earnings growth, future profitability and the earnings multiple that analysts believe the company can support. The narrative links those three elements into a single path for fair value. The interesting part is how much of that path depends on margin strength rather than very fast revenue growth.

    Result: Fair Value of $72.25 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the Boston Scientific story can change quickly if Watchman growth continues to reset, or if regulatory and reimbursement setbacks pressure margins and earnings expectations.

    Find out about the key risks to this Boston Scientific narrative.

    Next Steps

    With Boston Scientific sitting between concern and optimism, now is a good time to review the full picture yourself and decide where you stand. To weigh up both the potential upsides and the key issues that investors are watching, start by checking the 4 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Boston Scientific?

    Do not stop with Boston Scientific. Use the tools at your fingertips to compare different kinds of opportunities and sharpen how you build your portfolio.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.